Informationen:
Fehler:
ID
14020
Beschreibung
A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01961882
Link
https://clinicaltrials.gov/show/NCT01961882
Stichworte
Versionen (1)
- 22.03.16 22.03.16 -
Hochgeladen am
22. März 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Acute Myeloid Leukemia NCT01961882
Eligibility Acute Myeloid Leukemia NCT01961882
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Acute Myeloid Leukemia NCT01961882
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Acute myeloid leukemia in remission
Item
Patients with aml who achieved first complete remission within one or two courses of standard induction therapy, and completed standard consolidation therapy (more than one course).
boolean
C0153886 (UMLS CUI [1])
Age
Item
Patients who are 60 years or older.
boolean
C0153886 (UMLS CUI [1])
Informed Consent
Item
Patients who have provided written informed consent within 90 days from the last dose of consolidation therapy on an informed consent form that has been approved by an institutional review board or independent ethics committee.
boolean
C0021430 (UMLS CUI [1])
Acute Promyelocytic Leukemia
Item
Patients who have acute promyelocytic leukemia (apl) with t(15;17) (q22;q12), (pml/rara) karyotype abnormalities, and other variant types.
boolean
C0023487 (UMLS CUI [1])
Peripheral Stem Cell Transplantation
Item
Patients who are scheduled for hematopoietic stem cell transplantation
boolean
C0242602 (UMLS CUI [1])
Drugs potentially affecting the immune system
Item
Patients who have received drugs potentially affecting the immune system within 4 weeks before starting imp administration or who may receive such drugs after start of the trial.
boolean
C1532237 (UMLS CUI [1])
Concurrent disease or psychiatric illness
Item
Patients who have a severe concurrent disease or psychiatric illness likely to interfere with participation in this trial.
boolean
C0205420 (UMLS CUI [1])
C0004936 (UMLS CUI [2])
C0525058 (UMLS CUI [3])
C0004936 (UMLS CUI [2])
C0525058 (UMLS CUI [3])
HIV positive
Item
Patients who are hiv antibody positive, hbv-dna positive or have unrecovered chronic hepatitis c with positive hcv antibody.
boolean
C0019699 (UMLS CUI [1])
C1168040 (UMLS CUI [2])
C1168040 (UMLS CUI [2])
cirrhosis
Item
Patients who have cirrhosis.
boolean
C0023890 (UMLS CUI [1])
Ineligibility
Item
Patients judged to be ineligible by the investigator (or subinvestigator) for any other reasons.
boolean
C1512714 (UMLS CUI [1])